Neuron23 is developing drugs that treat neurological conditions by penetrating the blood-brain barrier to reach disease targets in the central nervous system. The biotech’s lead program is a Parkinson’s disease drug candidate with features that could distinguish it from rival compounds that are aiming for the same target.
